Graves’ Disease Induced by Immune Checkpoint Inhibitors: A Case Report and Review of the Literature

Introduction: In the last few years, immune checkpoint inhibitors (ICPis) have become a common treatment of cancer. ICPis are associated with peculiar immune side effects, termed immune-related adverse events (irAEs). Thyroid disfunction is a common irAE, but clinical manifestation, severity, and pathogenesis can be variable. While destructive thyroiditis and hypothyroidism are the most common thyroid irAEs induced by ICPis, autoimmune hyperthyroidism (Graves’ disease) is rare. We describe a case of a Graves’ disease induced by anti-PD-1 therapy and we review the previous reports on this issue. Case Presentation: A 51-year-old man developed an overt autoimmune hyperthyroidism 2 months after he had started nivolumab (anti-PD-1) therapy for a metastatic non-small cell lung cancer. Although TSH-receptor autoantibodies (TRAb) were negative, the persistence of hyperthyroidism, the hypervascular pattern at thyroid ultrasound, and the high uptake at thyroid scintigraphy were all features suggestive of Graves’ disease. Methimazole was started with the prompt restoration of euthyroidism. TRAb remained undetectable during the entire follow-up. Conclusions: Autoimmune hyperthyroidism can be induced by anti-PD-1 treatment. TRAb were negative in both cases of nivolumab-induced Graves’ disease described to date. A correct differential diagnosis between destructive thyroiditis and autoimmune hyperthyroidism is crucial for the appropriate treatment.

[1]  M. Rotondi,et al.  Nivolumab Induced Thyroid Dysfunction: Unusual Clinical Presentation and Challenging Diagnosis , 2019, Front. Endocrinol..

[2]  F. Hodi,et al.  Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints. , 2018, Endocrine reviews.

[3]  G. Rabinowits,et al.  A case of Graves' ophthalmopathy associated with pembrolizumab (Keytruda) therapy. , 2018, Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus.

[4]  J. Mazières,et al.  Severe Inflammatory Ophthalmopathy in a Euthyroid Patient during Nivolumab Treatment , 2018, European Thyroid Journal.

[5]  A. Dietz,et al.  Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms , 2017, The Journal of clinical endocrinology and metabolism.

[6]  R. Plummer,et al.  Tremelimumab-Induced Graves Hyperthyroidism
 , 2017, European Thyroid Journal.

[7]  R. Gale,et al.  The Ocular Manifestations of Drugs Used to Treat Multiple Sclerosis , 2017, Drugs.

[8]  C. Rudin,et al.  Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  A. Joehlin-Price,et al.  Treatment of Ipilimumab Induced Graves' Disease in a Patient with Metastatic Melanoma , 2016, Case reports in endocrinology.

[10]  T. Fulcher,et al.  Thyroid-Like Ophthalmopathy in a Euthyroid Patient Receiving Ipilimumab , 2014, Orbit.

[11]  C. Marcocci,et al.  Diagnosis and classification of Graves' disease. , 2014, Autoimmunity reviews.

[12]  N. Venturi,et al.  Course of Graves Disease in Interferon-Treated Patients With Chronic Hepatitis C Virus Infection and in Uninfected Patients , 2013, Journal of Investigative Medicine.

[13]  D. Giavarina,et al.  TSH receptor autoantibody immunoassay in patients with Graves' disease: improvement of diagnostic accuracy over different generations of methods. Systematic review and meta-analysis. , 2012, Autoimmunity reviews.

[14]  D. Hinkle,et al.  Drug-induced graves disease from CTLA-4 receptor suppression. , 2011, Ophthalmic plastic and reconstructive surgery.

[15]  L. Min,et al.  Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy. , 2011, European journal of endocrinology.